Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Inhibikase Therapeutics, Inc. (IKT) had Return on Equity of -29.01% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-27.52M |
|
-- |
|
-- |
|
$28.59M |
|
$-28.59M |
|
$1.07M |
|
$-27.52M |
|
$-27.52M |
|
$-27.52M |
|
$-27.52M |
|
$-27.52M |
|
$-27.52M |
|
$-28.59M |
|
$-28.56M |
|
23.71M |
|
23.71M |
|
$-1.16 |
|
$-1.16 |
|
| Balance Sheet Financials | |
$98.45M |
|
$0.05M |
|
$0.15M |
|
$98.60M |
|
$3.73M |
|
-- |
|
-- |
|
$3.73M |
|
$94.87M |
|
$94.87M |
|
$94.87M |
|
69.36M |
|
| Cash Flow Statement Financials | |
$-19.15M |
|
$-37.00M |
|
$103.48M |
|
$9.17M |
|
$56.49M |
|
$47.33M |
|
$8.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
26.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.15M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-29.01% |
-29.01% |
|
-27.91% |
|
-29.01% |
|
$1.37 |
|
$-0.81 |
|
$-0.81 |
|